UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~May~~July ~~27,~~ 2026

Commission File Number: No. 001-42155

Ping An Biomedical Co., Ltd. ~~(Registrant’s Name)~~

~~22/F, China~~(Registrant’s ~~United Plaza, 1002-1008, Tai Nan West Street,~~Name)

~~Cheung Sha Wan~~22/F, ~~Kowloon,~~China ~~Hong~~United ~~Kong~~ Plaza

~~(Address of~~1002-1008, ~~Principal~~Tai ~~Executive~~Nan ~~Offices)~~West Street

~~Indicate by~~Cheung ~~check~~Sha ~~mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.~~Wan

Kowloon, Hong Kong

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

~~It was~~INFORMATION ~~previously~~CONTAINED ~~disclosed~~IN ~~that~~THIS onFORM ~~November~~6-K 24, 2025, that Ping An Biomedical Co., Ltd. (the Company) received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the closing bid price of the Company for the period from October 10, 2025 to November 20, 2025, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.REPORT

~~The Company~~Entry ~~received~~into aMaterial letter from Nasdaq on May 26, 2026, noting that while the Company’s listed security has not regained compliance with the minimum $1 bid price per share requirement, Staff has determined that the Company is eligible for an additional 180 calendar day period, or until November 23, 2026, to regain compliance. Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this additional time period the closing bid price of the Company’s security is at least $1 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance and the matter will be closed.Agreement

~~The Company~~Ping isAn ~~currently~~Biomedical ~~evaluating~~Co ~~options~~Ltd to(the ~~regain~~“Company”), through ~~compliance~~its ~~and~~wholly ~~intends~~owned tosubsidiary, ~~timely~~Meridian ~~regain~~Industries ~~compliance~~Limited, ~~with~~entered ~~Nasdaq’s~~into ~~continued~~a ~~listing requirement.~~sale ~~Although~~and ~~the~~purchase ~~Company~~deed ~~will~~with ~~use~~Multi ~~all~~Ridge ~~reasonable~~(Asia) ~~efforts~~Limited, dated toJuly ~~achieve~~2, ~~compliance~~2026 ~~with Rule 5550~~(athe “Deed”)~~(2)~~, ~~there~~pursuant ~~can~~to bewhich ~~no assurance that~~ the Company ~~will~~purchased becertain ~~able~~trademarks tofor ~~regain~~the ~~compliance~~consideration ~~with~~of, ~~that~~in aggregate ~~rule~~USD2,500,000. orCompletion ~~will~~of ~~otherwise~~the beDeed inoccurred ~~compliance~~on ~~with~~July ~~other~~10, ~~Nasdaq continued listing requirement~~2026.

A copy of the form SPA is furnished as Exhibit 99.1 to this Form 6-K.

Exhibits

Exhibit No.		Description of Exhibit
99.1		Ping An Sale and Purchase Deed

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PING AN BIOMEDICAL CO., LTD.
Date: May 27, 2026	By:	/s/ Pijun Liu
Date: July 20, 2026	By:	/s/ Pijun Liu
	Name:	Pijun Liu
	Title:	~~Chairperson~~Chairman of the Board of Directors

Filing Compare · Ping An Biomedical Co., Ltd.